Skip to content

Comparison of efficacy of two ophthalmic drops on decreasing intraocular pressure

Comparison of efficacy and side effects of Latanoprost versus Timolol on decreasing IOP in patients with glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015042021875N1
Enrollment
40
Registered
2016-09-18
Start date
2015-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma. Glaucoma, Glaucoma suspect

Interventions

Intervention 1: Intervention group: Latanoprost ophthalmic drop 0.005% dripping one drop in each eye every night for 3 months. Intervention 2: Control group: Timolol ophthalmic drop 0.5% dripping one
Treatment - Drugs
Intervention group: Latanoprost ophthalmic drop 0.005% dripping one drop in each eye every night for 3 months.
Control group: Timolol ophthalmic drop 0.5% dripping one drop in each eye twice a day for 3 months.

Sponsors

Vice chancellor for research and technology of Islamic Azad University of Shahrood
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of open angle glaucoma symptoms; ocular hypertension includes patients with increased IOP; glaucomatous cupping (cup to disc ratio between 0.4 - 0.7; disc-cup asymmetry>0.2; notching of the rim; enlargement of the cup; bleeding of the rim of the disc; degeneration of the nerve fiber layer) Exclusion criteria: Secondary causes of increasing IOP; cup to disc ratio>0.7; IOP>30 mmHg in each stage of the disease; existing of any other ocular disorder except glaucoma; corrected vision less than 20/50; bradycardia; asthma; COPD; consumption of any drug affecting IOP for example beta blockers, corticosteroids, carbonic anhydrase inhibitors, nitrates and alpha 2 agonists; discontent of patient.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Tonometry. Timepoint: Before intervention, if the first wash out period is needed every 2 weeks during 4 weeks, at the end of the first week, the first and third month, every 2 weeks during 4 weeks in the second wash out period and at the end of the first week, the first and third month after the second wash out period. Method of measurement: Applanation Haag-Streit tonometer.

Secondary

MeasureTime frame
Refraction. Timepoint: Before intervention, at the end of the third month, at the end of the sixth month. Method of measurement: Refractor.;Gonioscopy. Timepoint: Before intervention, at the end of the third month, at the end of the sixth month. Method of measurement: Slit lamp.;Appointment of cup to disc ratio. Timepoint: Before intervention, at the end of the third month, at the end of the sixth month. Method of measurement: Slit lamp.;Eye irritation. Timepoint: Before intervention, if the first wash out period is needed every 2 weeks during 4 weeks, at the end of the first week, the first and third month, every 2 weeks during 4 weeks in the second wash out period and at the end of the first week, the first and third month after the second wash out period. Method of measurement: Questionnaire and examination by slit lamp.;Blurred vision. Timepoint: Before intervention, if the first wash out period is needed every 2 weeks during 4 weeks, at the end of the first week, the first and third month, every 2 weeks during 4 weeks in the second wash out period and at the end of the first week, the first and third month after the second wash out period. Method of measurement: Questionnaire and examination by slit lamp.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Ebrahimi

Imam Hossein Hospital of Shahrood

n.ebrahimi@iau-shahrood.ac.ir; gnaang2002@yahoo.com; neginiphone6p@gmail.com+98 23 3234 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026